Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-05-01

Clinical Trial Update: 4 Weeks Treatment of Type II Diabetic Patients With BI 44847 [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating four weeks of BI-44847 in adults with Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BI 44847

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED